Last week, NCPA and NACDS met with the Centers for Medicare & Medicaid Services to discuss our legal arguments on the Medicare Drug Price Negotiation (MDPN) program. Specifically, NCPA and NACDS argued that PBMs have to pay a negotiated price that is no lower than the maximum fair price and cover acquisition cost plus a commensurate professional dispensing fee in line with Medicaid fee-for-service, and be paid within Medicare prompt pay requirements. Further, we argued that manufacturers or CMS should pre-fund and float the MDPN program, not pharmacies, and that no DIR or other fees should be assessed on prescriptions in the MDPN program. For our full legal analysis and comments, see here.
NCPA
